2019-10-03 08:45
At the conference, Pontus Nobréus will address how liquid biomarkers can contribute with fundamental information and to a more effective process in the development of oncology drugs. DiviTum® is a cell proliferation biomarker and a valuable...
2019-09-18 08:00
The presentation will be held in English and will be followed by a questions and answers session. Questions can be asked via the telephone conference or in written form via the audiocast. No pre-registration is needed. Participant dial in number DK: +4578150109...
2019-09-18 08:00
Under the agreement, the DiviTum® blood assay will be used to analyze blood samples taken from participants in S0226, which between 2004 and 2009 enrolled 707 postmenopausal women with metastatic breast cancer at 73 hospitals, clinics, and cancer...
2019-09-17 08:00
The authors depicture the biological drivers behind CDK4/6 resistance, succeeded by how DiviTumÒ can contribute to identifying patients where an early switch to an alternative treatment can improve patient outcome and support treatment decisions...
2019-08-29 08:00
Significant events during the first quarter Significant events after the end of the period CEO’s comments Commercialization of DiviTum® for breast cancer During the first quarter of the new financial year, we achieved several important milestones...
2019-08-28 07:55
Based on the feedback from the FDA, Biovica has now a clear path to a 510(k) submission and clearance for DiviTum. In the supplement II process, topics such as intended use, clinical validation plan and predicate device were discussed. This is the third...
2019-07-25 12:16
On the 22nd of July, Biovica had fruitful meeting with the FDA regarding Supplement II that discusses the approach for clinical validation of DiviTum. Next step is to document the conclusions from the meeting, which the FDA will review and signoff. This...
2019-06-28 08:00
”A very positive fiscal year 2018/2019 is summarized in the annual report. For example, we have presented positive results from clinical trials in collaboration with leading oncologists, that has highlighted the value of DiviTum before and during...
2019-06-14 08:00
Significant events during the fourth quarter Significant events after the end of the period CEO's comments Commercialization of DiviTum® for breast cancer During the fourth quarter, we achieved several important milestones for launching DiviTum®...
2019-05-22 09:45
DiviTum® has to date been investigated in seventeen clinical studies, of which eight were within the breast cancer area. In breast cancer, over 1,000 patients have participated, where the majority have been patients with metastatic breast cancer (n=845)...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects